Metatron Long Term Equity Fund’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.99M Sell
18,000
-16,000
-47% -$1.55M 0.96% 30
2026
Q2
$2.66M Buy
+34,000
New +$2.32M 1.21% 25

Other funds holding HALO

Metatron Long Term Equity Fund's HALO Position: Q3 2026 in Review

Metatron Long Term Equity Fund reduced its Halozyme (HALO) stake by 47% in Q3 2026, selling an estimated $1.55M and leaving 18,000 shares worth $1.99M. The position accounts for 0.96% of the portfolio, ranked #30.

Metatron Long Term Equity Fund first reported a position in HALO in Q2 2026 and has held it in 2 quarters since. The position peaked at $2.66M in Q2 2026. 774 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Metatron Long Term Equity Fund held 18,000 shares of Halozyme worth $1.99M as of Q3 2026.
  • Metatron Long Term Equity Fund sold 16,000 Halozyme shares in Q3 2026, an estimated $1.55M.
  • Halozyme made up 0.96% of Metatron Long Term Equity Fund's portfolio in Q3 2026, its #30 holding.
  • Metatron Long Term Equity Fund first reported a position in Halozyme in Q2 2026 and has held it in 2 quarters since.
  • Metatron Long Term Equity Fund's Halozyme position peaked at $2.66M in Q2 2026.
  • 774 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Metatron Long Term Equity Fund's 13F filing for Q3 2026, filed 4 Nov 2026.